Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

video_2_edelbaum-mp4

October 8, 2018October 8, 2018

Published by

View all posts by

Published October 8, 2018October 8, 2018

Post navigation

Previous Post video_2_edelbaum-mp4

Leave a Reply Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Put Your Money Where Your Mouth Is January 24, 2023
Alvotech’s Ustekinumab Biosimilar Application With the FDA: Decision Expected Before End of Year January 9, 2023
Celltrion Files FDA Application for Subcutaneous Form of Infliximab January 4, 2023
40th Biosimilar Approved: Fresenius Kabi Gets FDA’s Nod on Idacio® December 15, 2022
PBM Trade Association Offers Key Changes to Improve Biosimilar Competitiveness December 12, 2022
Biogen Announces Submission of Its 351(k) Application for Actemra® Biosimilar December 9, 2022
J&J Slaps Patent Suit on Amgen Over Impending Stelara^® Biosimilar December 2, 2022
A Conversation With Ian Henshaw November 29, 2022
Lilly’s Rezvoglar Joins the Ranks of the Interchangeable Insulins November 18, 2022
OptumRx Reveals a 2023 Decision on Adalimumab Biosimilars November 16, 2022

Recent Comments

	Celltrion's Pen… on The Implications of Celltrion’…
	40th Biosimilar Appr… on FDA Approves Fresenius Kabi’s…
	Biogen Announces Sub… on Tocilizumab Biosimilars Approa…
	J&J Slaps Patent… on Ustekinumab Biosimilars Update
	J&J Slaps Patent… on Preliminary Phase 3 Study Data…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

Put Your Money Where Your Mouth Is
Biosimilar Approval Status
Hyrimoz
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
The Evolution of the Biosimilars Market
Tocilizumab Biosimilars Approaching: Developments on Three Fronts
Tanvex BioPharma Receives Complete Response Letter on Its Filgrastim Biosimilar Application
Amjevita
Lilly to Launch Authorized Generic for Humalog
Biosimilar Clinical Trial Costs in Terms of Expense and Time

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2022 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.